Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 11—November 2023
CME ACTIVITY - Synopsis

Campylobacter fetus Invasive Infections and Risks for Death, France, 2000–2021

Souheil ZayetComments to Author , Timothée Klopfenstein, Vincent Gendrin, Jean-baptiste Vuillemenot, Julie Plantin, Lynda Toko, Nour Sreiri, and Pierre-Yves Royer
Author affiliation: Nord Franche-Comté Hospital, Trévenans, France

Main Article

Table 2

Secondary localizations, therapeutic management, and outcomes of patients with Campylobacter fetus infections among patients with and without bacteremia, Nord Franche-Comté Hospital, Trévenans, France, 2000–2021*

Characteristics
All patients, n = 33 Patients with no C. fetus bacteremia, n = 12 Patients with C. fetus bacteremia, n = 21 p value
Secondary localizations†
Site infection
Total 7/33 (21) 0/12 7/21 (33) 0.03
Mycotic aneurysm 3/33 (9.0) 0/12 3/21 (14.3) 0.28
Endocarditis 1/33 (3.0) 0/12 1/21 (4.8) >0.9
Infection associated with a medical device 1/33 (3.0) 0/12 1/21 (4.8) >0.9
Thrombophlebitis 1/33 (3.0) 0/12 1/21 (4.8) >0.9
Bone or joint infection 1/33 (3.0) 0/12 1/21 (4.8) >0.9
Skin or soft tissue/abscesses 0/33 (0) 0/12 0/21 (0) NA
Meningitis
0/33 (0)
0/12
0/21 (0)
NA
Antimicrobial therapy 0.6
Amoxicillin 0/29 (0) 0/9 0/20 (0)
Amoxicillin–clavulanic acid 12/29 2/9 10/20 (50)
Imipenem 2/29 (6.9) 0/9 2/20 (10)
Gentamicin 3/29 (10) 0/9) 3/20 (15)
Azithromycin 1/29 (3.4) 1/9 (11) 0/20 (0)
Ciprofloxacin 3/29 (10) 2/9 (22) 1/20 (5.0)
Other
11/29 (38)
3/9 (33)
8/20 (40)

No. antimicrobial drugs/patient 0.065
0 4/29 (17) 2/9 (22) 2/20 (10)
1 11/29 (38) 5/9 (56) 6/20 (30)
2 10/29 (34) 2/9 (22) 8/20 (40)
3
4/29 (14)
0/9
4/20 (20)

Dual-therapy regimens
Amoxicillin/clavulanic acid + gentamicin 3/10 (30) 0/2 3/8 (38)
Amoxicillin/clavulanic acid + azithromycin 1/10 (10) 0/2 1/8 (12)
Amoxicillin/clavulanic acid + ciprofloxacin 2/10 (20) 0/2 2/8 (25)
Amoxicillin/clavulanic acid + doxycycline 3/10 (30) 2/2 (100) 1/8 (12)
Imipenem + gentamicin 1/10 (10) 0/2 1/8 (12)
Treatment duration, d (SD)
8 (8)
5 (5)
9 (8)
0.2
Outcomes and mortality rates
Long-term complications, n = 33
Total 1/33 (3.0) 0/12 1/21 (4.8) >0.9
Aneurysmal rupture/aortic dissection 1/33 (3.0) 0/12 1/21 (4.8) >0.9
Acute coronary syndrome 0/33 (0) 0/12 0/21 (0) NA
Irritable bowel syndrome 0/33 (0) 0/12 0/21 (0) NA
GBS (polyradiculoneuritis) 0/33 (0) 0/12 0/21 (0) NA
Surgery‡ 5/31 (16.1) 1/10 4/21 (19) 0.6
Relapse§ 2/33 (6) 0/12 2/21 (9.5) 0.5
Transfer to intensive care 4/33 (12) 0/12 4/21 (19) 0.3
Septic shock 4/33 (12) 0/11 4/21 (19) 0.3
Infection-related mortality 6/29 (21) 1/8 (12) 5/21 (24) 0.6
30-day mortality rate¶
10/33 (30) 3/12 (25) 7/21 (33) 0.9

*Values are no./total (%) except as indicated. Boldface indicates p<0.05 or a significant trend defined by p<0.06. Blank cells for p values indicate no p value was calculated. GBS, Guillain-Barré syndrome; NA, not applicable. †Mycotic aneurysm (n = 3) with infectious native aortic aneurysm (n = 2); prosthetic aortic valve and a positive culture of the aneurysm after surgery (n = 1); prosthetic valve endocarditis (n = 1) with typical oscillating vegetation (15 mm) confirmed by transthoracic echocardiography; abdominal aorta thrombophlebitis (n = 1); hematogenous medical device infection with a percutaneous implantable port-related infection (n = 1); osteoarticular (n = 1) with glenohumeral shoulder arthritis and a positive culture of the articular fluid after surgery, suggesting a contiguous infection. ‡Four patients with bacteremia caused by C. fetus underwent surgery: mycotic aneurysm (n = 2), endocarditis (n = 1), and septic arthritis (n = 1). §Two patients exhibited a relapse with fever after 26 and 50 d; the second patient died of septic shock during the second episode. The first patient received ciprofloxacin orally for 5 d, and the second patient received IV vancomycin for 7 d. ¶Among the 7 bacteremic patients who died, 2 died in the context of evolutive/expanding malignancy (independently of the bacteremia).

Main Article

Page created: September 06, 2023
Page updated: October 17, 2023
Page reviewed: October 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external